These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 24114056)

  • 1. Overexpression of membrane proteins in primary and metastatic gastrointestinal neuroendocrine tumors.
    Carr JC; Sherman SK; Wang D; Dahdaleh FS; Bellizzi AM; O'Dorisio MS; O'Dorisio TM; Howe JR
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3(0 3):S739-S746. PubMed ID: 24114056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression accurately distinguishes liver metastases of small bowel and pancreas neuroendocrine tumors.
    Sherman SK; Maxwell JE; Carr JC; Wang D; Bellizzi AM; Sue O'Dorisio M; O'Dorisio TM; Howe JR
    Clin Exp Metastasis; 2014 Dec; 31(8):935-44. PubMed ID: 25241033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiation of small bowel and pancreatic neuroendocrine tumors by gene-expression profiling.
    Carr JC; Boese EA; Spanheimer PM; Dahdaleh FS; Martin M; Calva D; Schafer B; Thole DM; Braun T; O'Dorisio TM; O'Dorisio MS; Howe JR
    Surgery; 2012 Dec; 152(6):998-1007. PubMed ID: 23158174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GIPR expression in gastric and duodenal neuroendocrine tumors.
    Sherman SK; Maxwell JE; Carr JC; Wang D; O'Dorisio MS; O'Dorisio TM; Howe JR
    J Surg Res; 2014 Aug; 190(2):587-93. PubMed ID: 24565507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Pancreas as a Site of Metastasis or Second Primary in Patients with Small Bowel Neuroendocrine Tumors.
    Scott AT; Pelletier D; Maxwell JE; Sherman SK; Keck KJ; Li G; Dillon JS; O'Dorisio TM; Bellizzi AM; Howe JR
    Ann Surg Oncol; 2019 Aug; 26(8):2525-2532. PubMed ID: 31011904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis.
    Duerr EM; Mizukami Y; Ng A; Xavier RJ; Kikuchi H; Deshpande V; Warshaw AL; Glickman J; Kulke MH; Chung DC
    Endocr Relat Cancer; 2008 Mar; 15(1):243-56. PubMed ID: 18310291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EPB41L5 is Associated With the Metastatic Potential of Low-grade Pancreatic Neuroendocrine Tumors.
    Saller J; Seydafkan S; Shahid M; Gadara M; Cives M; Eschrich SA; Boulware D; Strosberg JR; Aejaz N; Coppola D
    Cancer Genomics Proteomics; 2019; 16(5):309-318. PubMed ID: 31467225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNAs associated with small bowel neuroendocrine tumours and their metastases.
    Miller HC; Frampton AE; Malczewska A; Ottaviani S; Stronach EA; Flora R; Kaemmerer D; Schwach G; Pfragner R; Faiz O; Kos-Kudła B; Hanna GB; Stebbing J; Castellano L; Frilling A
    Endocr Relat Cancer; 2016 Sep; 23(9):711-26. PubMed ID: 27353039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Function and clinical relevance of RHAMM isoforms in pancreatic tumor progression.
    Choi S; Wang D; Chen X; Tang LH; Verma A; Chen Z; Kim BJ; Selesner L; Robzyk K; Zhang G; Pang S; Han T; Chan CS; Fahey TJ; Elemento O; Du YN
    Mol Cancer; 2019 May; 18(1):92. PubMed ID: 31072393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pancreastatin predicts survival in neuroendocrine tumors.
    Sherman SK; Maxwell JE; O'Dorisio MS; O'Dorisio TM; Howe JR
    Ann Surg Oncol; 2014 Sep; 21(9):2971-80. PubMed ID: 24752611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors.
    Scott AT; Weitz M; Breheny PJ; Ear PH; Darbro B; Brown BJ; Braun TA; Li G; Umesalma S; Kaemmer CA; Maharjan CK; Quelle DE; Bellizzi AM; Chandrasekharan C; Dillon JS; O'Dorisio TM; Howe JR
    Clin Cancer Res; 2020 Apr; 26(8):2011-2021. PubMed ID: 31937620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in gene expression in small bowel neuroendocrine tumors associated with progression to metastases.
    Keck KJ; Breheny P; Braun TA; Darbro B; Li G; Dillon JS; Bellizzi AM; O'Dorisio TM; Howe JR
    Surgery; 2018 Jan; 163(1):232-239. PubMed ID: 29154080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences between Well-Differentiated Neuroendocrine Tumors and Ductal Adenocarcinomas of the Pancreas Assessed by Multi-Omics Profiling.
    Starzyńska T; Karczmarski J; Paziewska A; Kulecka M; Kuśnierz K; Żeber-Lubecka N; Ambrożkiewicz F; Mikula M; Kos-Kudła B; Ostrowski J
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32586046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors.
    Sampedro-Núñez M; Luque RM; Ramos-Levi AM; Gahete MD; Serrano-Somavilla A; Villa-Osaba A; Adrados M; Ibáñez-Costa A; Martín-Pérez E; Culler MD; Marazuela M; Castaño JP
    Oncotarget; 2016 Feb; 7(6):6593-608. PubMed ID: 26673010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastatic pancreatic neuroendocrine tumors have decreased somatostatin expression and increased Akt signaling.
    Tran CG; Scott AT; Li G; Sherman SK; Ear PH; Howe JR
    Surgery; 2021 Jan; 169(1):155-161. PubMed ID: 32611516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is Multifocality an Indicator of Aggressive Behavior in Small Bowel Neuroendocrine Tumors?
    Choi AB; Maxwell JE; Keck KJ; Bellizzi AJ; Dillon JS; OʼDorisio TM; Howe JR
    Pancreas; 2017 Oct; 46(9):1115-1120. PubMed ID: 28902780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NESP55, a novel chromogranin-like peptide, is expressed in endocrine tumours of the pancreas and adrenal medulla but not in ileal carcinoids.
    Jakobsen AM; Ahlman H; Kölby L; Abrahamsson J; Fischer-Colbrie R; Nilsson O
    Br J Cancer; 2003 Jun; 88(11):1746-54. PubMed ID: 12771991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastric inhibitory polypeptide receptor (GIPR) is a promising target for imaging and therapy in neuroendocrine tumors.
    Sherman SK; Carr JC; Wang D; O'Dorisio MS; O'Dorisio TM; Howe JR
    Surgery; 2013 Dec; 154(6):1206-13; discussion 1214. PubMed ID: 24238043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinically Significant Differences in Ki-67 Proliferation Index Between Primary and Metastases in Resected Pancreatic Neuroendocrine Tumors.
    Richards-Taylor S; Tilley C; Jaynes E; Hu H; Armstrong T; Pearce NW; Plant R; Cave J
    Pancreas; 2017; 46(10):1354-1358. PubMed ID: 28984786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberration of ARID1A Is Associated With the Tumorigenesis and Prognosis of Sporadic Nonfunctional Pancreatic Neuroendocrine Tumors.
    Han X; Chen W; Chen P; Zhou W; Rong Y; Lv Y; Li JA; Ji Y; Chen W; Lou W; Xu X
    Pancreas; 2020 Apr; 49(4):514-523. PubMed ID: 32282764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.